Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H30N2O5S2 |
Molecular Weight | 466.614 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3(C[C@H]2C(O)=O)SCCS3
InChI
InChIKey=HRWCVUIFMSZDJS-SZMVWBNQSA-N
InChI=1S/C22H30N2O5S2/c1-3-29-21(28)17(10-9-16-7-5-4-6-8-16)23-15(2)19(25)24-14-22(30-11-12-31-22)13-18(24)20(26)27/h4-8,15,17-18,23H,3,9-14H2,1-2H3,(H,26,27)/t15-,17-,18-/m0/s1
DescriptionSources: https://www.drugs.com/international/spirapril.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01348 | https://www.ncbi.nlm.nih.gov/pubmed/18154140 | https://www.ncbi.nlm.nih.gov/pubmed/15490771 | https://www.ncbi.nlm.nih.gov/pubmed/15752941
Sources: https://www.drugs.com/international/spirapril.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB01348 | https://www.ncbi.nlm.nih.gov/pubmed/18154140 | https://www.ncbi.nlm.nih.gov/pubmed/15490771 | https://www.ncbi.nlm.nih.gov/pubmed/15752941
Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2544729 |
67.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | RENORMAX Approved UseUnknown Launch Date7.8865918E11 |
|||
Primary | RENORMAX Approved UseUnknown Launch Date7.8865918E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
81.6 μg/L |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
SPIRAPRILAT plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
37.85 μg/L |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
SPIRAPRILAT plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
846.75 μg × h/L |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
SPIRAPRILAT plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
152.5 μg × h/L |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
SPIRAPRILAT plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.85 h |
6 mg 1 times / day multiple, oral dose: 6 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
SPIRAPRILAT plasma | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
Other AEs: Cough, Dizziness... Other AEs: Cough (3.8%) Sources: Dizziness (5.3%) Fatigue (6%) Headache (9%) Oedema (3%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Oedema | 3% | 24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
Cough | 3.8% | 24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
Dizziness | 5.3% | 24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
Fatigue | 6% | 24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
Headache | 9% | 24 mg 1 times / day steady, oral (max) Recommended Dose: 24 mg, 1 times / day Route: oral Route: steady Dose: 24 mg, 1 times / day Sources: |
unhealthy, adult n = 133 Health Status: unhealthy Condition: hypertension Age Group: adult Sex: M+F Population Size: 133 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. | 1995 May |
|
Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension. | 1999 Feb |
|
[Effect of angiotensin converting enzyme inhibitor spirapril on dimensions of experimental myocardial infarction, development of ischemic tachyarrhythmias, and ischemic adaptation of the heart]. | 2002 |
|
Effects of antihypertensive therapy on hemorheological profiles in female hypertensive patients with initially low or high whole blood viscosity. | 2002 |
|
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. | 2002 |
|
[Influence of ACE inhibitor spirapril on left ventricular hypertrophy]. | 2002 Dec 5 |
|
[Hypertensive patient with diabetes. "Blood pressure cosmetics" are not enough here]. | 2002 Jun 13 |
|
[Open trial using ACE inhibitor. Left ventricular hypertrophy diminishes]. | 2002 Nov 28 |
|
Antiproteinuric versus antihypertensive effects of high-dose ACE inhibitor therapy. | 2002 Sep |
|
[Blood pressure lowering by the ACE-inhibitor spirapril. "24-hour efficacy of real once daily application of spirapril (HERAS Study)"]. | 2003 Oct 2 |
|
[Blood pressure lowering by the ACE-inhibitor spirapril. "24-hour efficacy of real once daily application of spirapril (HERAS study)"]. | 2003 Oct 9 |
|
Central angiotensin II controls alcohol consumption via its AT1 receptor. | 2005 Sep |
|
[Quadropril (spirapril) in the treatment of isolated systolic hypertension in patients with type 2 diabetes mellitus]. | 2006 |
|
[Advantages of long-term controlled stepwise therapy of arterial hypertension with the use of angiotensin converting enzyme inhibitor spirapril]. | 2006 |
|
[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome]. | 2006 |
|
[Effect of spirapril on remodeling of the heart in patients with mild and moderate arterial hypertension]. | 2007 |
|
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. | 2008 Mar 18 |
|
Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. | 2008 Nov |
|
Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. | 2010 May |
Sample Use Guides
The daily dose is 6 mg, the frequency of application is 1 time / day. After 4-6 weeks, in the absence of a satisfactory therapeutic effect, the dose can be increased.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22197392
Pooled human liver microsomes were obtained from Pfizer Global Supply and the tested compounds were acquired from Pfizer Global Material Management. Each incubation contained tested compounds (Spirapril) (1 mkM), microsomes (0.25 lM protein), NADPH regenerating system (1 mM NADP+, 5 mM isocitric acid and 1 unit/ mL isocitric dehydrogenase), MgCl2 (1 mM) and potassium phosphate buffer (100 mM at pH 7.4). This mixture was incubated at 37 _C for 0, 5, 10, 20, 30 and 60 min before quenching with acetonitrile. Control incubations were prepared using the same procedure without adding the catalytic cofactor NADPH. Individual samples were then analyzed in a ‘trap-and-elute’ mode using LC/MS
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
||
|
WHO-VATC |
QC09AA11
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
||
|
WHO-ATC |
C09AA11
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C052555
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
C66560
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
SPIRAPRIL
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
100000083823
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
m10150
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1044300
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
2474
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
6006
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL431
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
SUB10620MIG
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
36908
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
DB01348
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
96U2K78I3V
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
83647-97-6
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
6575
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY | |||
|
5311447
Created by
admin on Fri Dec 15 16:21:51 UTC 2023 , Edited by admin on Fri Dec 15 16:21:51 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD